Multimodality treatment of noninflammatory stage IIIb breast cancer

Gliński, Bogdan; Pawlicki, Marek; Reinfuss, Marian; Skołyszewski, J; Brandys, Anna; Krzemieniecki, Krzysztof; Żuchowska, Beata; Mituś, Jerzy; Stelmach, Andrzej; Walasek, Tomasz

doi:10.1002/(sici)1096-9098(199711)66:3<179::aid-jso5>3.0.co;2-9

Cited by 5 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Series in the literature that review the need for multimodal therapy for lesions deemed “unresectable” or “inoperable” typically include either few smaller SI lesions (31) or provide few or no details about the sizes of those primaries at presentation (32, 33). We question the necessity of preoperative chemotherapy for the smallest of these lesions and believe that specific investigation is warranted if sufficient power could be achieved.…”

Section: Discussionmentioning

confidence: 99%

Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?

Silverman

Ruth

Sigurdson

et al. 2014

Journal of the American College of Surgeons

View full text Add to dashboard Cite

Background Nonmetastatic non-inflammatory invasive breast cancers having skin involvement (SI) are classified as T4b, regardless of size. This study evaluated disease specific survival (DSS) to determine whether size should be considered for these lesions, rather than grouping them all into Stage III. Study Design Surveillance Epidemiology and End Results data linked to Medicare claims were reviewed. SI and nonSI tumors were reclassified using AJCC 7th Edition groupings using tumor size and nodal involvement alone without considering SI (neostage). DSS was adjusted for demographics, histology and treatment using competing risk methods with propensity score-based weighting and bootstrap standard errors. Results Among 924 SI patients diagnosed between 1992 and 2005, tumors were 0.1–2.0, 2.1–5.0, and >5.0 cm in 11.6%, 51.1%, and 37.3% of cases, respectively. There were no nodal metastases in 22.3%, 1–3 positive nodes in 31.7%, 4–9 positive in 28.6% and ≥10 positive in 17.4% of cases. For SI patients, adjusted 5-year DSS was 95.8% [95%CI: 95.6–96.0] for neostage I, declining progressively to 36.4% [95%CI: 33.8–39.2] for neostage IIIC patients. Adjusted 5-year DSS for SI and nonSI tumors (n=66,185) was similar for neostage I, IIA, and IIB, and markedly lower for IIIA and IIIC. Adjusted DSS for SI IIIA was similar to nonSI IIIC. Conclusions Noninflammatory SI breast cancers have widely varied DSS that differs by tumor size and nodal involvement, and therefore should not all be stage III. SI should be subordinate to T and N groupings to classify SI with nonSI lesions having similar prognoses.

show abstract

Section: Discussionmentioning

confidence: 99%

Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?

Silverman

Ruth

Sigurdson

et al. 2014

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

Noninflammatory breast carcinoma with skin involvement

Güth

Moch

Herberich

et al. 2004

Cancer

View full text Add to dashboard Cite

This article describes a systematic miniplant‐based approach to rapid development of simulated moving bed (SMB) chromatography applications. The methodology involves analysis of single‐column pulse tests to screen adsorbents and operating conditions and to determine initial values of profile advancement factors used to specify flow rates for an initial SMB miniplant experiment. A lumped‐parameter linear driving force rate‐based model is developed by fitting process data from a single miniplant run. The data are fit in a two‐step procedure involving initial determination of effective adsorption isotherm constants as best‐fit parameters with subsequent adjustment of calculated mass transfer coefficients to refine the data fit. The resulting simulation is used to guide further miniplant work and minimize experimental effort. The methodology is illustrated with miniplant data for a binary protein separation showing excellent agreement between model results and process data generated over a wide range of operating conditions. © 2009 American Institute of Chemical Engineers AIChE J, 2009

show abstract

Locoregional Therapy Following Neoadjuvant Chemotherapy: an Evolving Paradigm of Treatment Individualization

Mamounas

Breast Cancer and Molecular Medicine

View full text Add to dashboard Cite

Multimodality treatment of noninflammatory stage IIIb breast cancer

Cited by 5 publications

References 39 publications

Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?

Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?

Noninflammatory breast carcinoma with skin involvement

Locoregional Therapy Following Neoadjuvant Chemotherapy: an Evolving Paradigm of Treatment Individualization

Contact Info

Product

Resources

About